Targeted Disease(s):
Pulmonary Fibrosis

Purpose of Study:

The HARBOR Study is evaluating the safety and effectiveness of a potential medicine (HZN-825) that may slow disease progression in participants with idiopathic pulmonary fibrosis (IPF).

Study Dates:
August 25, 2021 - September 30, 2023

Type of Study:

Study Design:
Controlled Design

Study Location:

Lead Institution:
Horizon Therapeutics

Funding Source:
Horizon Therapeutics Identifier:

Register for Trial
Asthma Basics Workshop - National
, | May 07, 2024
Asthma Basics Workshop - National
, | May 15, 2024